Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
2005-04-26
2005-04-26
Guzo, David (Department: 1636)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
C424S093100, C424S093200, C424S093600, C514S04400A, C435S320100, C536S023100, C536S023200, C536S023400, C604S508000, C604S509000, C604S096010
Reexamination Certificate
active
06884431
ABSTRACT:
The present invention is directed to a method of vascular proliferative disease by administering in vivo a gene encoding p27.
REFERENCES:
patent: 5328470 (1994-07-01), Nabel et al.
patent: 5672508 (1997-09-01), Gyuris et al.
patent: 5688665 (1997-11-01), Massague et al.
patent: 5863904 (1999-01-01), Nabel et al.
patent: 5962424 (1999-10-01), Hallahan et al.
patent: 6110744 (2000-08-01), Fang et al.
patent: 6218372 (2001-04-01), Nabel et al.
patent: 6242575 (2001-06-01), Massague et al.
patent: 6316208 (2001-11-01), Roberts et al.
patent: 6355774 (2002-03-01), Massague et al.
patent: 6541197 (2003-04-01), Link, Jr. et al.
patent: WO 9518824 (1995-07-01), None
patent: WO 9602140 (1996-02-01), None
patent: WO 9625507 (1996-08-01), None
Craig et al. Proc. Annu. Meet. Assoc. Cancer Res. 37: A13 “Effects of a Recombinant Adenovirus Vector Expressing p27 on Cell Growth, Cell Cycle, Cyclin Kinases and Apoptosis”.
PCT Notification of Transmission of The International Search Report or the Declaration (8 pages), Mailed Jan. 14, 1999.
Chen et al., “Downregulation of Cyclin-dependent Kinase 2 Activity and Cyclin A Promoter Activity in Vascular Smooth Muscle Cells by p27KIP1, an Inhibitor of Neointima Formation in the Rat Caroid Artery,” pp. 2234-2341, J. Clin. Invest. 99 (10) 1997.
Toyoshima et al., “p27, a Novel Inhibitor of G1 Cyclin-Cdk Protein Kinase Activity, Is Related to p21,” Cell, vol. 78, Jul. 15, 1994, pp. 67-74.
Tanner et al., “Expression of Cyclin-Dependent Kinase Inhibitors in Vascular Disease,” pp. 396-403, Cir. Res. 1998; vol. 82.
Tanner et al., “Gene Transfer of p27KIP2and p21CIP1Cyclin-Dependent Kinase Inhibitors, But Not p16INX, Negatively Regulate VSMC Proliferation Through Differential Effects on Kinase Activity,” Circulation vol. 96(8): SUPPL. p. 15 10/97.
Braun-Dullaeus et al., Regulation of Vascular Smooth Muscle Cell Proliferation by the Cyclin-Dependent Kinase Inhibitor p27KIP1, one page J. Invest. Med., vol. 45(3) p. 224A 3/97.
Hideo Toyoshima and Tony Hunter, “p27, a Novel Inhibitor of G1 Cyclin-Cdk Protein Kinase Activity, Is Related to p21”, Cell, vol. 78, pp. 67-74, Jul. 15, 1994.
Kornelia Polyak et al., “Cloning of p27KIP1, a Cyclin-Dependent Kinase Inhibitor and a Potential Mediator of Extracellular Antimitogenic Signals”, Cell, vol. 78, pp. 59-66, Jul. 15, 1994.
Steve Coats et al., “Requirement of p27KIP1for Restriction Point Control of the Fibroblast Cell Cycle”, Science, vol. 272, May 10, 1996, pp. 877-880.
Koyama et al. Fibrillarcollagen inhibits arterial smooth muscle proliferation through regulation of cdk2 inhibitors, Cell, vol. 87, 1069-1078, Dec. 13, 1996.
Nabel Elizabeth G.
Nabel Gary J.
Brinks Hofer gilson & Lione
Guzo David
The Regents of the University of Michigan
LandOfFree
Method for treating proliferative diseases with p27 and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating proliferative diseases with p27 and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating proliferative diseases with p27 and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3416103